On September 25, Humana rose 5.79% in regular trading, trading at $403.18 per share, with turnover of $161 million. The rally was primarily driven by Barclays upgrading the stock from Equalweight to Overweight, with a significantly raised price target of $515 from $407, implying approximately 28% upside from the current level.

The Barclays upgrade adds to a growing chorus of bullish institutional sentiment. BofA Securities previously raised its target to $510 from $500, while Leerink Partners set a $513 target alongside an upgrade to Outperform. Evercore ISI also upgraded the stock to Outperform with a $480 target. The FactSet consensus mean price target has risen to $425.46 with an average Overweight rating, reflecting a broad shift in analyst expectations.

On the fundamental side, Humana delivered Q2 adjusted EPS of $7.61, beating the Street estimate of $7.22, on revenue of $40.87 billion, up 26% year-over-year. The company reaffirmed full-year adjusted EPS guidance of at least $9.00. The company also maintained its quarterly dividend at $0.885 per share and expanded strategic partnerships including a kidney care agreement with DaVita.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)